ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

Guan Ji lin*; Zhong Wen zhao; An She juan; Yang Jin ji; Su Jian; Chen Zhi hong; Yan Hong hong; Chen Zhi yong; Huang Zhi min; Zhang Xu chao; Nie Qiang; Wu Yi long广东省人民医院
Annals of Surgical Oncology2013-4DOI: 10.1245/s10434-012-2754-z
23被引6阅读
引用收藏
分享

摘要

The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led to inconsistent results in previous reports. <br>The KRAS and EGFR genes were examined in 1935 consecutive patients with non-small cell lung cancer. All patients were divided into KRAS mutation (KRAS group), EGFR mutation (EGFR group), and KRAS/EGFR wild type (WT group) groups. Randomly selected cases were paired with patients with the KRAS mutation, the EGFR mutation, and KRAS/EGFR wild type patients according to tumor, node, metastasis stage, time of first visit within 1 year, and pathology. Progression-free survival (PFS) and overall survival were evaluated by Kaplan-Meier and Cox models. <br>The KRAS mutation rate for lung adenocarcinoma was 5.90 %. The overall survival was 14.47, 20.57, and 42.73 months for the KRAS group, WT group, and EGFR group, respectively (P < 0.001). Multivariate analysis indicated that KRAS mutation status was an independent prognostic factor (hazard ratio 2.69, 95 % confidence interval 1.91-3.80, P < 0.001). No difference was found in PFS and tumor responsiveness between patients with a KRAS mutation and those with wild type KRAS/EGFR for chemotherapy and EGFR tyrosine kinase inhibitors (TKI). PFS did not significantly differ for chemotherapy among the three groups (P = 0.270). <br>KRAS mutation is a poor prognosis factor, but it is not an independent predictor of response to EGFR-TKI or chemotherapy in patients with lung cancer.

相关
加载中…
  • Clinical characteristics and prognostic value of theKRAS G12Cmutation in Chinese non-small cell lung cancer patients
    Liu, Si-Yang; Sun, Hao; Zhou, Jia-Ying; Jie, Guang-Ling; Xie, Zhi; Shao, Yang; Zhang, Xian; Ye, Jun-Yi; Chen, Chun-Xiang; Zhang, Xu-Chao; Zhou, Qing; Yang, Jin-Ji; Wu, Yi-Long*Biomarker Research, 2020, 8(1): 22.被引 38
  • Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial
    Li, Xiang-Meng; Li, Wen-Feng; Lin, Jun-Tao; Yan, Hong-Hong; Tu, Hai-Yan; Chen, Hua-Jun; Wang, Bin-Chao; Wang, Zhen; Zhou, Qing; Zhang, Xu-Chao; Su, Jian; Chen, Rui-Lian; Wu, Yi-Long*; Yang, Jin-Ji*Clinical Lung Cancer, 2021, 22(2): 100-+.被引 28
  • KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma
    Li, Na; Tian, Yue; Liu, Xin; Pan, Ciming; Xue, Jian*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2023, 102(52): e36597.
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Surgical Oncology
发表日期
2013-04
卷期
第 20 卷, 第 4 期
页码
1381-1388
DOI
10.1245/s10434-012-2754-z
语言
ENGLISH
期刊等级
Q1
成果收录
SCI
资助标注
National Natural Science Foundation of China [81001031, 30871 126]; Industry Technology Research and Development Project of Guangdong Science and Technology Department [2011A030 400010]; Guangzhou Science and Information Technology Bureau [2011Y2-00014]

作者

  • G

    Guan Ji lin (通讯) (第一作者)

    guangdong gen hosp

  • Z

    Zhong Wen zhao

查看全部 12 位作者收起作者
  • A

    An She juan

  • Y

    Yang Jin ji

  • S

    Su Jian

  • C

    Chen Zhi hong

  • Y

    Yan Hong hong

  • C

    Chen Zhi yong

  • H

    Huang Zhi min

  • Z

    Zhang Xu chao

  • N

    Nie Qiang

  • W

    Wu Yi long

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417